We recently published a list of Did Jim Cramer Get These 23 Stocks Right?. In this article, we are going to take a look at ...

American pharmaceutical giant Johnson & Johnson (JNJ) is boosting its U.S. investments by 25% to more than $55 billion over ...

Johnson & Johnson (NYSE: JNJ) has kicked off construction on a $2 billion biologics manufacturing facility in Eastern North ...

Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending ...

Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...

Johnson & Johnson (JNJ) announced its plans to invest over $55 billion over the next four years in the U.S. to strengthen its ...

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American ...

Johnson Johnson (NYSE: JNJ) announced plans to invest over $55 billion in the United States over the next four years, ...

Johnson & Johnson (NYSE:JNJ) on Friday announced plans to boost its U.S. investments to more than $55B over the next four ...